Cannabis Companies' Gains - U.S. Versus Canada: Averages Can Be Deceiving, Irrational Market Behavior To Blame?

Author: Nicolás Jose Rodriguez | April 25, 2024 09:57am

Recent insights from Viridian Capital Advisors shed light on the bewildering trends in cannabis stocks. Year-to-date (YTD) data indicates that U.S. multi-state operators (MSOs) and Canadian licensed producers (LPs) have experienced drastically different fates.

At a glance, U.S. MSOs show an average return of 26.4%, towering over Canadian LPs' modest 1.3%.

However, this picture is deceiving.

If we remove the outliers—Trulieve Cannabis (OTC:TCNNF), which saw significant gains, and Tilray Brands (NASDAQ:TLRY), which experienced sharp declines—the true performance is closer: MSOs at 16.79% and LPs at 25.97%.

Market Irrationality

According to Viridian, these fluctuations suggest an irrational market behavior. Before 4/20 a few Canadian stocks rose by more than 50% YTD. The volatility reflects not just company performance but broader economic factors like regulatory changes and market speculation.

Understanding Outliers: Tilray Brands, Inc. Struggles Despite Revenue Gains

Despite operational advances, Tilray faces considerable market challenges. The company reported a 30% year-over-year increase in third-quarter net revenue to $188.3 million but also a significant net loss of $105 million, a slight improvement from the previous year’s $1.2 billion loss.

However, a revision in the financial outlook—including an expected inability to generate positive adjusted free cash flow for fiscal year 2024—prompted a sharp 22.2% stock price drop.

Analyst Caution And Long-Term Performance Concerns

Market analysts remain cautious, downgrading Tilray's stock target amidst ongoing operational challenges. Over the past five years, Tilray’s stock has declined annually by 48.47%. Continued trends could diminish stock value to as low as $0.07, highlighting a critical need for operational improvements.

Trulieve Cannabis Corp.: Strategic Success And Market Growth

Conversely, Trulieve has surpassed revenue expectations with Q4 reporting $287 million, credited to strategic cash preservation and growth-focused investments.

With Germany’s recent cannabis legalization and potential market expansion in Florida, Trulieve is poised for significant growth, potentially increasing its valuation by over 150% with the upcoming 2024 legalization ballot.

Dominance And Expansion In Core Markets

Trulieve maintains a strong market presence, leading in flower and extract sales, particularly in Florida where it operates 193 dispensaries. The company's proactive expansion and strategic acquisitions, including the HEXO acquisition, solidify its market dominance and operational efficiency, supporting robust stock performance despite broader market volatility.

Why It Matters

For new investors, understanding these dynamics is crucial. The cannabis market is influenced by regulatory shifts, such as those in Canada, and the potential for new markets like Germany.

This makes the sector particularly prone to rapid changes and speculation.

Recognizing these factors helps investors discern between temporary hype and genuine growth potential, providing a safeguard against common market pitfalls and helping to navigate the sector's notorious highs and lows.

Photo: AI-Generated Image. 

Posted In: TCNNF TLRY